Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1126/scitranslmed.abf1906 http://scihub22266oqcxt.onion/10.1126/scitranslmed.abf1906 33820835!8284311!33820835     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33820835&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Transl+Med 2021 ; 13 (593): ä Nephropedia Template TP {{tp|p=33820835|t=2021. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates |pdf=|usr=}}{{33820835}} gab.com Text The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates JO: Sci Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=33820835 #FOAvip Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may bridge widespread vaccination campaigns and offer a treatment solution in populations less responsive to vaccination. Here, we report that high-throughput microfluidic screening of antigen-specific B cells led to the identification of LY-CoV555 (also known as bamlanivimab), a potent anti-spike neutralizing antibody from a hospitalized, convalescent patient with coronavirus disease 2019 (COVID-19). Biochemical, structural, and functional characterization of LY-CoV555 revealed high-affinity binding to the receptor-binding domain, angiotensin-converting enzyme 2 binding inhibition, and potent neutralizing activity. A pharmacokinetic study of LY-CoV555 conducted in cynomolgus monkeys demonstrated a mean half-life of 13 days and a clearance of 0.22 ml hour(-1) kg(-1), consistent with a typical human therapeutic antibody. In a rhesus macaque challenge model, prophylactic doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract in samples collected through study day 6 after viral inoculation. This antibody has entered clinical testing and is being evaluated across a spectrum of COVID-19 indications, including prevention and treatment. Twit Text FOAVip The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates ????Sci Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=33820835 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33820835 #FOAvip English Wikipedia <ref>{{Cite pmid|33820835}}</ref> The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates #MMPMID33820835 Jones BE; Brown-Augsburger PL; Corbett KS; Westendorf K; Davies J; Cujec TP; Wiethoff CM; Blackbourne JL; Heinz BA; Foster D; Higgs RE; Balasubramaniam D; Wang L; Zhang Y; Yang ES; Bidshahri R; Kraft L; Hwang Y; Zentelis S; Jepson KR; Goya R; Smith MA; Collins DW; Hinshaw SJ; Tycho SA; Pellacani D; Xiang P; Muthuraman K; Sobhanifar S; Piper MH; Triana FJ; Hendle J; Pustilnik A; Adams AC; Berens SJ; Baric RS; Martinez DR; Cross RW; Geisbert TW; Borisevich V; Abiona O; Belli HM; de Vries M; Mohamed A; Dittmann M; Samanovic MI; Mulligan MJ; Goldsmith JA; Hsieh CL; Johnson NV; Wrapp D; McLellan JS; Barnhart BC; Graham BS; Mascola JR; Hansen CL; Falconer E Sci Transl Med 2021[May]; 13 (593): ä PMID33820835show ga Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may bridge widespread vaccination campaigns and offer a treatment solution in populations less responsive to vaccination. Here, we report that high-throughput microfluidic screening of antigen-specific B cells led to the identification of LY-CoV555 (also known as bamlanivimab), a potent anti-spike neutralizing antibody from a hospitalized, convalescent patient with coronavirus disease 2019 (COVID-19). Biochemical, structural, and functional characterization of LY-CoV555 revealed high-affinity binding to the receptor-binding domain, angiotensin-converting enzyme 2 binding inhibition, and potent neutralizing activity. A pharmacokinetic study of LY-CoV555 conducted in cynomolgus monkeys demonstrated a mean half-life of 13 days and a clearance of 0.22 ml hour(-1) kg(-1), consistent with a typical human therapeutic antibody. In a rhesus macaque challenge model, prophylactic doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract in samples collected through study day 6 after viral inoculation. This antibody has entered clinical testing and is being evaluated across a spectrum of COVID-19 indications, including prevention and treatment. |*Antibodies, Neutralizing/immunology[MESH] |*COVID-19/immunology/prevention & control[MESH] |Animals[MESH] |Antibodies, Viral/*immunology[MESH] |Macaca mulatta[MESH] |SARS-CoV-2[MESH]The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infe(epmc).pdf DeepDyve Pubget Overpricing